A pilot trial of the mTOR (mammalian target of rapamycin) inhibitor RAD001 in patients with advanced B-CLL

Author： Decker Thomas  

Publisher： Springer Publishing Company

ISSN： 0939-5555

Source： Annals of Hematology, Vol.88, Iss.3, 2009-03, pp. : 221-227

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Molecular Cytogenetic Analysis of B-CLL Patients with Aggressive Disease

By Gozzetti Alessandro   Crupi Rosaria   Tozzuoli Daniela   Raspadori Donatella   Forconi Francesco   Lauria Francesco  

Hematology, Vol. 9, Iss. 5-6, 2004-10 ,pp. : 383-385

Maney Publishing

Access to resources Recommend Favorite

Role of Mammalian Target of Rapamycin in Atherosclerosis

By  

Current Molecular Medicine, Vol. 18, Iss. 4, 2018-05 ,pp. : 216-232

Bentham Science Publishers

Access to resources Recommend Favorite

Mammalian Target of Rapamycin as a Therapeutic Target in Leukemia

By  

Current Molecular Medicine, Vol. 5, Iss. 7, 2005-11 ,pp. : 653-661

Bentham Science Publishers

Access to resources Recommend Favorite

The angiogenic status of B-CLL B cells: role of the VEGF receptors

By Kay N.E.  

Leukemia Research, Vol. 28, Iss. 3, 2004-03 ,pp. : 221-222

Elsevier

Access to resources Recommend Favorite

mTOR Inhibition and the Tumor Vasculature

By  

Current Angiogenesis, Vol. 1, Iss. 1, 2012-04 ,pp. : 11-19

Bentham Science Publishers

Access to resources Recommend Favorite